The immunotherapy era of myeloma: Monoclonal antibodies, vaccines, and adoptive T-cell therapies

Valentina Hoyos, Ivan Borrello

Research output: Contribution to journalReview article

Abstract

The treatment of multiple myeloma has evolved significantly over the last decades from primarily alkylator-based chemotherapeutic agents with minimal efficacy to the introduction of more effective agents including immune modulators and proteasome inhibitors, which have changed the landscape of therapy for this disease. We are now entering a new era that will increasingly integrate immunotherapy into standard treatment. This review discusses the currentimmune-based strategies currently approved, as well as various immune approaches being actively investigated including monoclonal antibodies, checkpoint inhibitors, vaccines, and adoptive T-cell therapies.

Original languageEnglish (US)
Pages (from-to)1679-1687
Number of pages9
JournalBlood
Volume128
Issue number13
DOIs
StatePublished - Sep 29 2016

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'The immunotherapy era of myeloma: Monoclonal antibodies, vaccines, and adoptive T-cell therapies'. Together they form a unique fingerprint.

  • Cite this